MRKR
Marker Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$17.99M
P/E Ratio
—
EPS
$-0.79
Beta
1.47
52W High
$2.46
52W Low
$0.81
50-Day MA
$1.48
200-Day MA
$1.32
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based immunotherapies and peptide-based vaccines for the treatment of hematologic malignancies and solid tumor indications. The company is headquartered in Houston, Texas.
Fundamentals
| Revenue (TTM) | $3.55M |
| Gross Profit (TTM) | $-8.25M |
| EBITDA | $-11.79M |
| Operating Margin | -170.70% |
| Return on Equity | -68.80% |
| Return on Assets | -37.80% |
| Revenue/Share (TTM) | $0.23 |
| Book Value | $1.01 |
| Price-to-Book | 1.40 |
| Price-to-Sales (TTM) | 5.07 |
| EV/Revenue | 0.721 |
| EV/EBITDA | -0.22 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -51.00% |
| Shares Outstanding | $12.94M |
| Float | $13.81M |
| % Insiders | 5.49% |
| % Institutions | 24.25% |
Analyst Ratings
Consensus ($7.87 target)
3
BuyData last updated: 4/8/2026